Advertisement
Advertisement
U.S. Markets open in 4 hrs 23 mins
Advertisement
Advertisement
Advertisement
Advertisement

Clearmind Medicine Inc. (CMNDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.46550.0000 (0.00%)
At close: 12:10PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4655
Open0.4655
BidN/A x N/A
AskN/A x N/A
Day's Range0.4655 - 0.4655
52 Week Range0.3511 - 0.7300
Volume375
Avg. Volume3,131
Market Cap15.309M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-0.0460
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Clearmind Medicine Engages the Independent Trading Group as a Market Maker and Thunder11 as a PR Agency

    TORONTO, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, announces that, subject to regulatory approval, it has engaged the services of Independent Trading Group ("ITG") to provide market-making services. ITG will trade shares of the Company

  • GlobeNewswire

    Clearmind Medicine to Host “Psychedelic for Alcoholism: From Molecule to Medicine” Virtual Event on January 26

    Clearmind’s Management Team Will Explain the Regulatory Process Required for Clearmind’s Patented MEAI Molecule to Become an FDA Approved Medicine for Treating Alcohol Use Disorder and Binge Drinking TORONTO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated he

  • GlobeNewswire

    Clearmind Medicine's VP of Business Development Presented at The Canadian Psychedelics Association Event

    The CPA's Panel for physicians and medical professionals addressed "New Psychedelic Substances" TORONTO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announces that its newly appointed VP Business Development, psychedelic medicine ex

Advertisement
Advertisement